Treatments · Therapeutic reasoning with a clinical spine
Learn dermatologic therapies through mechanism, selection, risk, monitoring, and meaningful comparison—not disconnected drug lists.
For: medical students, rotators, interns, and residents reviewing foundations. No dosing or individualized prescribing guidance.
Choose your depth
Every path uses the same six questions so the learning stays coherent.
The DermPrep therapeutic framework
Learner boundary: recognize, understand, compare, and explain. Patient-specific selection, prescribing, dose changes, and discontinuation belong with the supervising clinical team and current prescribing information.
Treatment discovery
A small, complete launch library designed to expand without empty categories.
8 complete treatment cards
Topical · Foundation · 10 min
Mechanism: broadly reduce cutaneous inflammation through glucocorticoid-receptor effects.
Major concept: potency, vehicle, body site, duration, and patient context shape selection.
Common confusion: treating every topical steroid as interchangeable.
Open pathway →Topical · Foundation · 8 min
Mechanism: alter retinoid-receptor signaling and follicular keratinization.
Major concept: irritation and pregnancy considerations are not the same across all formulations.
Common confusion: assuming “retinoid” means one indication or one risk profile.
View snapshot →Topical · Rotation · 9 min
Mechanism: inhibit calcineurin-dependent T-cell activation.
Major concept: site and steroid-sparing goals can influence their role.
Common confusion: equating warning language with an absolute contraindication.
View snapshot →Systemic · Rotation · 12 min
Mechanism: modify retinoid-receptor signaling, differentiation, and disease-relevant cellular activity.
Major concept: indication, reproductive risk, adverse effects, and monitoring are agent-specific.
Common confusion: treating isotretinoin and acitretin as equivalent.
View snapshot →Systemic · Advanced Rotation · 14 min
Mechanism: class members affect different immune or proliferative pathways.
Major concept: organ risk, interactions, onset, duration, and monitoring burden differ.
Common confusion: “systemic immunosuppressant” is not one interchangeable class.
View snapshot →Biologic · Advanced Rotation · 15 min
Mechanism: target selected cytokines, receptors, or immune pathways.
Major concept: disease indication, phenotype, comorbidities, infection considerations, and administration shape choice.
Common confusion: a shared route does not imply shared indication or safety.
Compare classes →Small molecule · Advanced Rotation · 15 min
Mechanism: inhibit intracellular enzymes or signaling pathways.
Major concept: route, indication, label warnings, interactions, and monitoring are agent-specific.
Common confusion: applying one drug’s warning or indication to an entire category.
Open safety comparison →Procedural · Rotation · 10 min
Mechanism: use physical, light-based, destructive, or locally delivered approaches.
Major concept: indication, operator skill, anatomy, expected response, and aftercare matter.
Common confusion: reading about a procedure is not procedural competency.
Connect to Procedures →We could not find a complete launch card for that search. Try a broader class, disease, mechanism, or route.
Complete treatment pathway
A model for how every treatment lesson connects mechanism to use.
Why this matters
A useful explanation connects the inflammatory process to the therapy, then asks whether potency, vehicle, site, age, disease extent, and treatment duration fit the clinical context.
Mechanism chain: glucocorticoid receptor → altered inflammatory gene signaling → reduced cutaneous inflammation.
Say it like this
Weak: “Use a steroid cream.”
Better: “A topical corticosteroid may fit this localized inflammatory eruption, but the body site, severity, vehicle, expected duration, and risk of local adverse effects should guide the specific choice with the supervising clinician.”
Why this treatment?
The logic becomes stronger when morphology and diagnosis support an inflammatory dermatosis, involvement is limited, and the chosen potency and vehicle fit the site. It becomes weaker when the diagnosis is uncertain, infection is plausible, the site is high risk, disease is extensive, or prior nonresponse suggests adherence, vehicle, potency, duration, or diagnosis should be reconsidered.
Why not that treatment?
A more potent topical corticosteroid can create unnecessary local risk on some sites; a lower-potency option may be inadequate for another presentation. The discriminating question is whether the treatment’s potency, vehicle, site, duration, and diagnosis align—not whether one product is universally superior.
What changes your choice?
Initial scenario: a localized inflammatory plaque on a thicker-skinned body site.
New information: the same morphology is now located on the eyelid of a young child, and the diagnosis is not yet secure. Site, age, diagnostic uncertainty, and risk now change the treatment discussion. Reassess rather than automatically carrying over the same plan.
Potency, vehicle, site, duration, and occlusion shape both effect and risk.
Explain why the class fits the inflammatory pattern and which contextual feature determines the specific choice.
Verify diagnosis, examine the treatment site, review prior use and response, and discuss selection with the supervising clinician.
Reassessment asks whether the eruption is improving, whether the diagnosis still fits, how and where the medication is being used, and whether local adverse effects or disease complications are emerging. The monitoring plan depends on the treatment and patient context.
Before assuming that a stronger therapy is needed, consider diagnostic mismatch, adherence, vehicle acceptability, inadequate potency or duration, persistent trigger, infection, disease extent, access, and incorrect application.
Age, pregnancy or lactation, body site, skin barrier, comorbidities, immune status, and concurrent treatments may change the discussion. Use current product information and guideline recommendations for patient-specific decisions.
Comparison mode
Select a lens. The table remains conceptual and avoids false equivalence.
| Question | Topical corticosteroid | Topical calcineurin inhibitor |
|---|
Class comparisons are orientation tools. Individual agents can differ in approved indication, age, route, contraindications, warnings, interactions, and monitoring.
Complete treatment-page standard
Sections appear only when relevant.
Overview, class, mechanism, common uses, learner level.
Place in therapy, administration framework, “why this,” and “why not that.”
Common effects, serious concerns, warnings, contraindication concepts, interactions, and population context.
What is followed, why it matters, and which risk it detects.
Clinically meaningful alternatives without artificial treatment ladders.
Communication, case change, retrieval practice, and next-best actions.
Common mistakes
Correct by tracing target → effect → clinical consequence → safety consequence.
Check the individual indication, route, population, warnings, and monitoring.
Use the exact regulatory language; warning, precaution, and contraindication are not synonyms.
Know what each check is intended to detect rather than memorizing an unexplained list.
Confirm current labeling and guidelines before patient-specific discussion.
Reassess diagnosis, adherence, duration, potency, access, triggers, and disease context first.
Commonly confused
A therapy may be discussed or used in a clinical context without having an FDA-approved indication for that exact disease, age, formulation, or route. State approval status precisely and verify it against current labeling.
A warning describes an important risk or precaution. A contraindication identifies a circumstance in which the product should not be used according to labeling. Do not collapse them.
Shared mechanisms can create shared concepts, but indications, trial evidence, warnings, interactions, and monitoring can remain agent-specific.
Explain the safety purpose of monitoring and identify whether a workflow comes from labeling, a guideline, or local practice.
If your attending asks
Name the target or pathway, the biologic effect, and the expected clinical consequence.
Discuss severity, site, age, pregnancy or lactation, comorbidities, infection risk, organ function, prior response, administration burden, monitoring, access, and patient goals only as relevant.
Connect each check to the safety concern or response question it is meant to detect.
Distinguish current FDA labeling from guideline recommendations and other clinical use. Verify rather than assume.
Retrieval practice
30-second recap
One thing to remember: the best answer is not a drug name—it is a defensible treatment rationale.
Next best actions
Also connects to Procedures, Visual Diagnosis, and the canonical Glossary.